✦ LIBER ✦

How Much and How Long: Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia

✍ Scribed by Elie Traer; Michael W. Deininger

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Chronic Myeloid Leukemia and Second-Gene

✍ Elias Jabbour; Hagop Kantarjian; Jorge Cortes 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 272 KB

Patient adherence to tyrosine kinase inh

✍ Elias J. Jabbour; Hagop Kantarjian; Lina Eliasson; A. Megan Cornelison; David Ma 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 833 KB

Adherence to oral tyrosine kinase inhibi

✍ Adam Gater; Louise Heron; Linda Abetz-Webb; John Coombs; Jeff Simmons; François 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 834 KB

Dual tyrosine kinase inhibitors in chron

✍ Martinelli, G; Soverini, S; Rosti, G; Baccarani, M 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 322 KB

Second-generation tyrosine kinase inhibi

✍ Ronan Swords; Yesid Alvarado; Jorge Cortes; Francis J. Giles 📂 Article 📅 2007 🏛 Current Science Inc. 🌐 English ⚖ 145 KB

Monitoring Patients with Chronic Myeloid

✍ Oehler, Vivian; Radich, Jerald P. 📂 Article 📅 2007 🏛 CIG Media Group, LP. 🌐 English ⚖ 210 KB